Principal Scientist, Protein Therapeutics
Gilead Sciences(1 month ago)
About this role
Gilead’s Biologics Engineering group within the Protein Therapeutics department is hiring a Principal Scientist to advance large-molecule drug candidates, including multispecific formats, novel antibody binding domains, and fusion proteins. The role owns biologics projects end-to-end from protein design through lead optimization in a highly matrixed R&D environment and includes people leadership and cross-functional partnering.
Required Skills
- Protein Engineering
- Antibody Engineering
- Multispecific Design
- Fusion Proteins
- Lead Optimization
- In Silico Design
- Structure-Based Design
- Fc Engineering
- Humanization
- Sequence Optimization
+19 more
Qualifications
- PhD in Biochemistry
- PhD in Structural Biology
- MS
- BS
About Gilead Sciences
gilead.comGilead Sciences is a biopharmaceutical company dedicated to transforming patient care by advancing therapeutics in areas like HIV, liver disease, cancer, and inflammation. With a strong commitment to innovation, Gilead leads in the research and development of new medicines, aiming to make the world a healthier place. Their portfolio includes breakthrough therapies and ongoing advancements across multiple therapeutic areas, supported by a robust pipeline of clinical trials. Gilead is recognized for its contributions to public health and its efforts to improve access to vital medications.
View more jobs at Gilead Sciences →Apply instantly with AI
Let ApplyBlast auto-apply to jobs like this for you. Save hours on applications and land your dream job faster.
More jobs at Gilead Sciences
Similar Jobs
Full-Time Template Job
Voyager Therapeutics(1 month ago)
Lead Researcher Antibody Discovery
St. Jude(3 months ago)
Advisor / Sr. Advisor - Protein Expression
LI Test Company(2 months ago)
Senior Scientist, Antibody and Protein Engineering
Regeneron Pharmaceuticals(1 month ago)
Senior Scientist, Molecular Discovery
MSD(1 month ago)
Director, Protein & Cell Sciences
Flagship Pioneering, Inc.(21 days ago)